MedTrace Logo

Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons

NCT02766686 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2023-02-08

No results posted yet for this study

Summary

ProtoChoice-P is a prospective multicenter trial to evaluate proton therapy in patients suffering from prostate cancer. Primary aim of the study is a decrease of moderate or severe genito-urinary or intestinal side effects (Common Terminology Criteria for Adverse Events (CTCAE) 4.0 grade 2 or higher) by the use of proton therapy. Secondary endpoints contain assessment of quality of life, biochemical recurrence and recurrence free survival as well as overall survival and economic comparison between photon and proton therapy.

Conditions

Interventions

RADIATION

Radiotherapy with protons

RADIATION

Radiotherapy with photons

Sponsors & Collaborators

  • German Consortium for Translational Cancer Research

    collaborator OTHER

  • National Center for Radiation Research in Oncology Dresden/Heidelberg

    collaborator OTHER

  • Radiation Oncology Working Group of the German Cancer Society

    collaborator OTHER

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Tobias Hölscher, Dr. · University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2024-02-29
Completion
2026-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766686 on ClinicalTrials.gov